摘要
目的通过研究介孔分子筛SBA-15对奥美沙坦的组装及释放情况,考察介孔分子筛对药物的缓释机制,开发新型药物载体材料。方法以三嵌段表面活性剂P123为模板剂,正硅酸乙酯(TEOS)为硅源,按照TEOS-P123(1∶0.017)的物质的量比,使用水热合成法合成介孔分子筛SBA-15。并利用溶剂挥发法将奥美沙坦组装于SBA-15分子孔道中,利用XRD、氮吸附、红外光谱法对组装前后的分子筛进行了表征,并进一步研究了组装于分子上的筛奥美沙坦在模拟胃液及模拟肠液中的释放情况。结果 XRD图谱、氮吸附脱附曲线、红外光谱图表征均表明奥美沙坦成功组装于SBA-15孔道内。吸附到介孔分子筛上的奥美沙坦酯在模拟胃液中5 h时仅释放了30%左右,较短时间内,组装体中奥美沙坦在模拟肠液中的释放速率高于其在模拟胃液中的释放速率,随时间延长两体系释放速率逐渐接近。结论介孔分子筛SBA-15对奥美沙坦具有明显的缓释作用。
OBJECTIVE To investigate the release mechanism of drugs assembled in the pores of mesoporeous molecular sieves and explore new materials for drug delivery by studying the release of olmesartan assembled in the pores of SBA-15.METHODS The mesoporous molecular sieves SBA-15 was prepared by hydrothermal method using triblock copolymer P123 as a template agent and tetraethyl orthosilicate（TEOS） as the silicon source.The molar ratio of TEOS and P123 was 1∶0.017.Olmesartan was assembled in the pores of the SBA-15 by evaporating the solvent.XRD,FT-IR,and N2-sorption were used to characterize the assemblies.The released rate of olmesartan assembled in the pores of SBA-15 was studied in artificial gastric juice and intestinal fluid.RESULTS The XRD,N2 adsorption curve,and infrared spectroscopy indicated that olmesartan was assembled in the pores of SBA-15 successfully.Only 30% olmesartan was released from the assemblies in the first 5 h in gastric juice,and the release rate of the olmesartan in intestinal fluid was higher than that in gastric juice within the first 15 h.CONCLUSION SBA-15 obviously decreases the released rate of olmesartan.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2011年第20期1577-1580,共4页
Chinese Pharmaceutical Journal
基金
山东省卫生厅资助课题(2007HW036)
关键词
介孔分子筛
SBA-15
奥美沙坦
缓释
组装体
mesoporous molecular siere
SBA-15
olmesartan
sustained-release
assembly
